MILREM-ROBOTICS
25.11.2021 09:02:10 CET | Business Wire | Press release
The iMUGS Consortium, in charge of a 32,6 MEUR project developing the European standard unmanned ground system (UGS), demonstrated how defence forces can use tactical 4G/5G communications networks and UGS’ equipped with ISR and signal intelligence payloads, jammers, acoustic sensors, and various other technology to conduct missions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211125005387/en/
The demonstration that was performed in September in Latvia, was led by LMT, a member of the integrated Modular Unmanned Ground System (iMUGS) consortium, with the support of the project coordinator Milrem Robotics and featured an ensemble of different technology.
Latvian National Armed Forces used two Milrem Robotics’ THeMIS Unmanned Ground Vehicles (UGV) during two scenarios to display the benefits of teaming up manned units with unmanned systems.
One THeMIS UGV was equipped with an Intelligence, surveillance, and reconnaissance (ISR) payload, Signal Intelligence antenna (SIGINT) provided by The Electronic Communications Office of Latvia, Rheinmetall’s Rapid Obscuring System (ROSY) Smoke Grenade Launcher, Bittium’s Vehicular Software Defined Radios (Tough SDR Vehicular), and FN Herstal’s deFNder Light Remote Weapon Station (RWS). The RWS integration was part of the demonstration, but not of the iMUGS project itself.
The second THeMIS, used as a mule for transporting the squad’s equipment, was equipped with Rantelon’s Improvised Explosive Device (IED) Jammer and Bittium’s Tough SDR Vehicular.
The units and UGVs used Bittium’s tactical communication network TAC WIN combined with LMT’s commercial 4G and a tactical 5G-SA bubble provided by Bittium and Cumucore.
In addition, Krauss-Maffei Wegmann’s (KMW) Dingo infantry mobility vehicle was used as the command centre from where UGVs were operated in Line of Sight (LOS) and Beyond the Line of Sight (BLOS) mode using Bittium’s SDR radios and to where the ISR and Signal Intelligence sensor feed was relayed and incorporated into LMT’s Battle Management System Viedsargs.
“The displayed scenarios showed that unmanned systems, enhanced with innovative communication systems and various defence technology, can be used for collecting and sharing tactical information, improve situational awareness, decrease troops physical load, and increase force protection,” explained Kuldar Väärsi, CEO of Milrem Robotics.
''For the first time ever, in a special network, a tactical network was connected with a stand-alone 5G network. This allowed communication between units and robots, as well as collecting information from sensors and placing this information into LMT’s Battle Management System "Viedsargs'','' said Ingmars Pukis, Vice President and Member of the Management Board of LMT.
Additional equipment used in the demonstration included: SRC Brasa's NATRIX UGV used for CASEVAC, high-speed First-Person View drone, Vertical Take-off, and Landing UAV STAR, and a gunshot detection and source recognition audio sensor by Riga Technical University (RTU).
The iMUGS project was launched in 2020 to develop a modular, cyber secure and scalable architecture for hybrid manned-unmanned systems. Its goal is to standardize a Europe-wide ecosystem for ground platforms, command, control and communication equipment, sensors, payloads, and algorithms. Addressed operational challenges include enhanced interoperability, increased situational awareness and faster decision-making.
The system will use an existing UGV – Milrem Robotics’ THeMIS – and a specific list of payloads.
The project’s progress is displayed during six demonstrations. „So far Milrem Robotics and LMT Innovations have set the bar very high. Which means we have some great things to wait for as the main results of the iMUGS projects are yet to be seen,“ said Martin Jõesaar from the Estonian Center for Defence Investments, the representative of the participating Member States in the iMUGS Project. The next demonstration will take place in Q1 of 2022 in Finland.
iMUGS is a cooperation between 13 parties: Milrem Robotics (project coordinator), Bittium, Diehl Defence, dotOcean, GMV Aerospace and Defence, Insta Advance, Krauss-Maffei Wegmann, Latvijas Mobilais Telefons (LMT), NEXTER Systems, Royal Military Academy of Belgium, Safran Electronics & Defense, Sol.One and Talgen Cybersecurity.
Watch the Demo 2 Scenarios here:
https://www.youtube.com/watch?v=-_iLCV3Ob2I
https://www.youtube.com/watch?v=HbK_ixrTuWU
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125005387/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
